Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Castro, Mónica ^b   Grau, Laura ^a   Puerta, Patricia ^a   Gimenez, Liliana ^b   Venditti, Julio ^c   Quadrelli, Silvia ^c   Sánchez Carbayo, Marta ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b Oncology Department   (Argentina)

^c HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL VOLTAGE DEPENDENT T TYPE ALPHA 1G SUBUNIT; HELICASE LIKE TRANSCRIPTION FACTOR; HISTONE H2FX; INHIBITOR OF DNA BINDING 4; ONCOPROTEIN; PROTEIN BNIP3; PROTEIN CACNA1A; PROTEIN SCGB3A1; TRANSFORMING GROWTH FACTOR BETA INDUCED FACTOR HOMEOBOX 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DNA METHYLATION; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVERALL SURVIVAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; AGED; COHORT ANALYSIS; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COHORT STUDIES; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77957896015     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-86     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009, 59(4):225-49. 10.3322/caac.20006, 19474385.
2. Herbst RS, Heymach JV, Lippman SM. Lung Cancer. J Med N Engl 2008, 359(13):1367-80.
3. Pérez-Soler R. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene 2009, 28(Suppl 1):S38-S45. 10.1038/onc.2009.200, 19680295.
4. Heller G, Zielinski CC, Zöchbauer-Müller S. Lung cancer: From single-gene methylation to methylome profiling. Cancer Metastasis Rev 2010, 29(1):95-107. 10.1007/s10555-010-9203-x, 20099008.
5. Belinsky SA. Gene promoter hypermethylation as a biomarker in lung cancer. Nature Cancer Rev 2004, 4(9):707-17.
6. Pfeifer GP, Rauch TA. DNA methylation patterns in lung cancer. Seminars in Cancer Biology 2009, 19(3):181-187. 10.1016/j.semcancer.2009.02.008, 2680753, 19429482.
7. Costello JF, Fruhwald MC, Smiraglia DJ. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000, 24(2):132-8. 10.1038/72785, 10655057.
8. Esteller M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 2002, 21(35):5427-5440. 10.1038/sj.onc.1205600, 12154405.
9. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2003, 3(6):415-28.
10. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054. 10.1056/NEJMra023075, 14627790.
11. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7(1):21-33. 10.1038/nrg1748, 16369569.
12. Hu YC, Sidransky D, Ahrendt SA. Molecular detection approaches for smoking associated tumors. Oncogene 2002, 21(48):7289-97. 10.1038/sj.onc.1205805, 12379873.
13. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD, Pfeifer GP. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007, 104(13):5527-32. 10.1073/pnas.0701059104, 1838508, 17369352.
14. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 2008, 112(6):1325-36. 10.1002/cncr.23312, 18286531.
15. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002, 30(12):e57. 10.1093/nar/gnf056, 117299, 12060695.
16. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005, 33(14):e128. 10.1093/nar/gni127, 1187824, 16106041.
17. Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP, Benninger MS. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006, 132(6):668-677. 10.1001/archotol.132.6.668, 16785414.
18. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007, 87(10):1055-65. 10.1038/labinvest.3700664, 17700563.
19. Berkhout M, Nagtegaal ID, Cornelissen SJ, Dekkers MM, van de Molengraft FJ, Peters WH, Nagengast FM, van Krieken JH, Jeuken JW. Chromosomal and methylation alterations in sporadic and familial adenomatous polyposis-related duodenal carcinomas. Mod Pathol 2007, 20(12):1253-62. 10.1038/modpathol.3800952, 17873900.
20. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, Errami A, Schouten JP, Meijer CJ, Snijders PJ, Steenbergen RD. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 2007, 97(10):1457-64. 10.1038/sj.bjc.6604055, 2360246, 17971771.
21. Chen K, Sawhney R, Khan M, Benninger MS, Hou Z, Sethi S, Stephen JK, Worsham MJ. Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2007, 133(11):1131-8. 10.1001/archotol.133.11.1131, 18025318.
22. Scott RH, Douglas J, Baskcomb L, Nygren AO, Birch JM, Cole TR, Cormier-Daire V, Eastwood DM, Garcia-Minaur S, Lapunzina P, Tatton-Brown K, Bliek J, Maher ER, Rahman N. Methylation-specific MLPA (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J Med Genet 2008, 45:106-113. 10.1136/jmg.2007.053207, 18245390.
23. Hess CJ, Errami A, Berkhof J, Denkers F, Ossenkoppele GJ, Nygren AO, Schuurhuis GJ, Waisfisz Q. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 2008, 49(6):1132-41. 10.1080/10428190802035990, 18569637.
24. Ewald C, Hofmann T, Kuhn SA, Deufel T, Beetz C, Kalff R. Methylation-specific multiplex ligation-dependent probe amplification in meningiomas. J Neurooncol 2008, 90(3):267-73. 10.1007/s11060-008-9672-8, 18763019.
25. Gylling A, Ridanpää M, Vierimaa O, Aittomäki K, Avela K, Kääriäinen H, Laivuori H, Pöyhönen M, Sallinen SL, Wallgren-Pettersson C, Järvinen HJ, Mecklin JP, Peltomäki P. Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer 2009, 124(10):2333-40. 10.1002/ijc.24230, 19173287.
26. Buyru N, Altinisik J, Ozdemir F, Demokan S, Dalay N. Methylation profiles in breast cancer. Cancer Invest 2009, 27(3):307-12. 10.1080/07357900802350814, 19194828.
27. Röhrs S, Dirks WG, Meyer C, Marschalek R, Scherr M, Slany R, Wallace A, Drexler HG, Quentmeier H. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 are indicative of MLL translocations in acute myeloid leukemia. Mol Cancer 2009, 8:86. 10.1186/1476-4598-8-86, 2770485, 19835597.
28. Berginc G, Bracko M, Glavac D. MS-MLPA reveals progressive age-dependent promoter methylation of tumor suppressor genes and possible role of IGSF4 gene in colorectal carcinogenesis of microsatellite instable tumors. Cancer Invest J 2010, 28(1):94-102.
29. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18(6):1059-1068. 10.1183/09031936.01.00275301, 11829087.
30. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, Sanchez-Carbayo M. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 2008, 98(2):466-73. 10.1038/sj.bjc.6604143, 2361432, 18087279.
31. Dawson-Saunders B, Trapp RG. Basic & Clinical Biostatistics. 1994, Norwalk, Connecticut, Appleton & Lange, 2.
32. Du Y, Carling T, Fang W, Piao Z, Sheu JC, Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res 2001, 61(22):8094-9.
33. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003, 94(7):589-92. 10.1111/j.1349-7006.2003.tb01487.x, 12841866.
34. Li QL, Kim HR, Kim WJ, Choi JK, Lee YH, Kim HM, Li LS, Kim H, Chang J, Ito Y, YoulLee K, Bae SC. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004, 314(1):223-8. 10.1016/j.bbrc.2003.12.079, 14715269.
35. Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T, Mori M. Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 2006, 15(1):129-35.
36. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008, 29(5):895-904. 10.1093/carcin/bgn017, 18308762.
37. Jin M, Kawakami K, Fukui Y, Tsukioka S, Oda M, Watanabe G, Takechi T, Oka T, Minamoto T. Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels. Cancer Sci 2009, 100(12):2325-30. 10.1111/j.1349-7006.2009.01321.x, 19764999.
38. Yoshino M, Suzuki M, Tian L, Moriya Y, Hoshino H, Okamoto T, Yoshida S, Shibuya K, Yoshino I. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int J Oncol 2009, 35(5):1201-9.
39. Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet 2005, 162(1):10-20. 10.1016/j.cancergencyto.2005.03.008, 16157195.
40. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, Jordan CD, Kiviat NB, Vesselle H. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2008, 17(3):645-54. 10.1158/1055-9965.EPI-07-2518, 2798850, 18349282.
41. Hawes SE, Stern JE, Feng Q, Wiens LW, Rasey JS, Lu H, Kiviat NB, Vesselle H. DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer 2009, PMID: 19945765.
42. Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004, 2(9):489-94.
43. Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, Tomlinson GE, Mastrangelo D, Pass HI, Brambilla E, Sathyanarayana UG, Czerniak B, Fujisawa T, Shimizu N, Gazdar AF. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 2005, 113(4):600-4. 10.1002/ijc.20622, 15472908.
44. Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, Hagen JA, Koss MN, Laird-Offringa IA. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 2007, 6:70. 10.1186/1476-4598-6-70, 2206053, 17967182.
45. Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004, 23(7):1405-11. 10.1038/sj.onc.1207291, 14661059.
46. Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, Hofmann HS, Silber RE, Burdach S, Hansen G. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 2005, 41(8):1223-36. 10.1016/j.ejca.2005.02.020, 15911247.
47. Suzuki M, Wada H, Yoshino M, Tian L, Shigematsu H, Suzuki H, Alaa M, Tamura H, Fujiwara T, Nagato K, Motohashi S, Moriya Y, Hoshino H, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, Yoshino I. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol 2010, 17(3):878-88. 10.1245/s10434-009-0739-3, 19841986.
48. Virmani A, Rathi A, Heda S, Sugio K, Lewis C, Tonk V, Takahashi T, Roth JA, Minna JD, Euhus DM, Gazdar AF. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer 2003, 107(3):341-5. 10.1002/ijc.11393, 14506731.
49. Kubo T, Yamamoto H, Ichimura K, Jida M, Hayashi T, Otani H, Tsukuda K, Sano Y, Kiura K, Toyooka S. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. Lung Cancer 2009, 65(3):328-32. 10.1016/j.lungcan.2008.12.001, 19144441.
50. Nagatake M, Osada H, Kondo M, Uchida K, Nishio M, Shimokata K, Takahashi T, Takahashi T. Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers. Cancer Res 1996, 56(8):1886-91.
51. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 2006, 12(24):7329-38. 10.1158/1078-0432.CCR-06-0894, 17189404.
52. Herbst A, Wallner M, Rahmig K, Stieber P, Crispin A, Lamerz R, Kolligs FT. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur J Gastroenterol Hepatol 2009, 21(5):565-9. 10.1097/MEG.0b013e328318ecf2, 19282772.
53. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA, Liang G. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005, 41(17):2769-78. 10.1016/j.ejca.2005.07.019, 16242928.